Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Jun 14;18(7):sfaf188.
doi: 10.1093/ckj/sfaf188. eCollection 2025 Jul.

Terlipressin for sinusoidal obstruction syndrome-associated acute kidney injury: a novel application

Callie J Meath  1 , Bindu Simon  2 , Rohtesh S Mehta  3 , Partow Kebriaei  3 , Jamie S Lin  2
Affiliations
Case Reports

Terlipressin for sinusoidal obstruction syndrome-associated acute kidney injury: a novel application

Callie J Meath et al. Clin Kidney J. .

Abstract

Sinusoidal obstruction syndrome (SOS) is a life-threatening complication of hematopoietic cell transplantation that can lead to multiorgan failure, including acute kidney injury (AKI) due to hepatorenal syndrome (HRS)-like physiology. Current supportive measures often fail in preserving renal function, and dialysis is associated with high mortality risk. Terlipressin, a vasopressin analog approved for HRS in cirrhosis, has not been previously described for SOS-AKI. We report the first detailed case of terlipressin improving renal function, restoring diuretic responsiveness, and preventing dialysis in a patient with SOS, highlighting its potential as a therapeutic option for SOS-related renal failure.

Keywords: acute kidney injury; hematopoietic cell transplant; hepatorenal syndrome; sinusoidal obstructive syndrome; terlipressin.

PubMed Disclaimer

Conflict of interest statement

None declared.

Figures

Figure 1:
Figure 1:
Trends in weight (a), serum creatinine level (b), and blood pressure (c). The red triangle marks the date of the transplant. Blue triangles indicate administration of midodrine and albumin. The gray shaded area indicates the period of terlipressin. The green dotted line indicates baseline levels.
See this image and copyright information in PMC

References

    1. Kim H, Ali R, Short S et al. AKI treated with kidney replacement therapy in critically Ill allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2024;59:178–88. 10.1038/s41409-023-02136-8 - DOI - PubMed
    1. Carreras E, Bertz H, Arcese W et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 1998;92:3599–604. - PubMed
    1. Renaghan AD, Jaimes EA, Malyszko J et al. Acute kidney injury and CKD associated with hematopoietic stem cell transplantation. Clin J Am Soc Nephrol 2020;15:289–97. 10.2215/CJN.08580719 - DOI - PMC - PubMed
    1. Wong F, Pappas SC, Curry MP et al. Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome. N Engl J Med 2021;384:818–28. 10.1056/NEJMoa2008290 - DOI - PubMed
    1. Mohty M, Malard F, Alaskar AS et al. Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a refined classification from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 2023;58:749–54. 10.1038/s41409-023-01992-8 - DOI - PubMed

Publication types

LinkOut - more resources